Naoya Akazawa

Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer

Daisuke Kotani, Eiji Oki, Yoshiaki Nakamura et al. · Nature Medicine · 2023 · 430 citations · Full text

Surgical Oncology, Oncology, Cancer Epidemiology +15

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal Cancer

Jun Watanabe, Kei Muro, Kohei Shitara et al. · JAMA · 2023 · 222 citations · Full text

ctDNA-based molecular residual disease and survival in resectable colorectal cancer

Yoshiaki Nakamura, Jun Watanabe, Naoya Akazawa et al. · Nature Medicine · 2024 · 132 citations · Full text

Interim Analysis, Prognostic Biomarkers, Surgical Oncology +14

Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer

Kohei Shitara, Kei Muro, Jun Watanabe et al. · Nature Medicine · 2024 · 87 citations · Full text

Association of circulating tumor DNA dynamics with clinical outcomes in the adjuvant setting for patients with colorectal cancer from an observational GALAXY study in CIRCULATE-Japan.

Masahito Kotaka, Hiromichi Shirasu, Jun Watanabe et al. · Journal of Clinical Oncology · 2022 · 61 citations

Surgical Oncology, Cancer Management, Adjuvant Chemotherapy +18